Cargando…

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease

The response to treatment with biologic drugs, in patients with Crohn’s disease, could be associated with changes in gut microbiota composition. The aim of our study was to analyse the modification of microbiota during adalimumab therapy in patients with Crohn’s disease. We performed a prospective s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribaldone, Davide Giuseppe, Caviglia, Gian Paolo, Abdulle, Amina, Pellicano, Rinaldo, Ditto, Maria Chiara, Morino, Mario, Fusaro, Enrico, Saracco, Giorgio Maria, Bugianesi, Elisabetta, Astegiano, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832711/ https://www.ncbi.nlm.nih.gov/pubmed/31601034 http://dx.doi.org/10.3390/jcm8101646

Ejemplares similares

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis
por: Carli, Edoardo, et al.
Publicado: (2020)

Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity (“lymphocytic enterocolitis”)?
por: Bonagura, Gabriele Antonio, et al.
Publicado: (2016)

Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Inflammatory Bowel Disease Nurse—Practical Messages
por: Rosso, Chiara, et al.
Publicado: (2021)

Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
por: Bretto, Elisabetta, et al.
Publicado: (2023)

Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

Predictive Factors of Surgical Recurrence in Patients with Crohn’s Disease on Long-Term Follow-Up: A Focus on Histology
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Comment on “Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2023)

A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Response to: Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2016)

Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Finally, it is Bismuth's Time
por: Ribaldone, Davide G., et al.
Publicado: (2017)

Strategies for Helicobacter pylori eradication in the year 2020
por: Pellicano, Rinaldo, et al.
Publicado: (2020)

Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn’s Disease: A Pilot Study
por: Cusato, Jessica, et al.
Publicado: (2021)

Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014
por: Saracco, Giorgio Maria, et al.
Publicado: (2016)

Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2023)

Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2021)

The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review
por: Armandi, Angelo, et al.
Publicado: (2021)

Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

2013 Update on Celiac Disease and Eosinophilic Esophagitis
por: Pellicano, Rinaldo, et al.
Publicado: (2013)

Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification
por: Olivero, Antonella, et al.
Publicado: (2022)

Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis
por: Rosso, Chiara, et al.
Publicado: (2022)

Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2022)

Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q71imeqqqqgf27m1g8i6f22ssq